Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France.

Date publication

janvier 2020

Journal

Journal of geriatric oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François

Tous les auteurs :
Elkrief A, Richard C, Malo J, Cvetkovic L, Florescu M, Blais N, Tehfe M, Messaoudene M, Gagné A, Orain M, Medjebar S, Wan-Chow-Wah D, Joubert P, Labbé C, Ghiringhelli F, Routy B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31948904

Résumé

Age-related immune remodelling is thought to be associated with resistance to immune checkpoint inhibitors (ICIs) in cancer. Patients older than 70 years, representing >50% of the population with non-small cell lung cancer (NSCLC) according to SEER database, are underrepresented in clinical trials exploring ICIs. The objective of this study was to determine if patients with NSCLC older than ≥70 years had inferior clinical outcomes with ICIs.

Référence

J Geriatr Oncol. 2020 Jan 13;: